![अदाणी रिपोर्ट मामले में सेबी ने हिंडनबर्ग को जारी किया कारण बताओ नोटिस](https://i-invdn-com.investing.com/news/LYNXMPED770B6_S.jpg)
कृपया अन्य खोज का प्रयास करें
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Peter Gibson | - | 2018 | Chairman of Product Development Advisory Board |
Rebecca Burgell | - | 2018 | Member of Product Development Advisory Board |
Barry Campbell | - | 2018 | Member of Product Development Advisory Board |
Nicholas Haslam | - | 2022 | Non-Executive Director |
Jakob Begun | - | 2018 | Member of Product Development Advisory Board |
Simon Keely | - | 2018 | Member of Product Development Advisory Board |
John Michailidis | - | 2022 | COO & Executive Director |
David Lionel Brookes | 64 | 2019 | Executive Chairman & MD |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है